| Nome |
# |
|
Correlazioni tra genotipo e fenotipo nelle sindromi mieloproliferative croniche Ph-negative, file e398c378-c80e-179a-e053-3705fe0a4cff
|
4.402
|
|
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele., file e398c378-a5d8-179a-e053-3705fe0a4cff
|
622
|
|
Current management strategies for polycythemia vera and essential thrombocythemia, file e398c381-a02d-179a-e053-3705fe0a4cff
|
572
|
|
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment., file e398c37b-a2ca-179a-e053-3705fe0a4cff
|
521
|
|
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)., file e398c37b-a620-179a-e053-3705fe0a4cff
|
465
|
|
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia., file e398c37b-a0bd-179a-e053-3705fe0a4cff
|
305
|
|
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation, file e398c37b-a050-179a-e053-3705fe0a4cff
|
291
|
|
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia., file e398c37b-a0ce-179a-e053-3705fe0a4cff
|
284
|
|
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis, file e398c379-988a-179a-e053-3705fe0a4cff
|
256
|
|
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia., file e398c37b-a688-179a-e053-3705fe0a4cff
|
256
|
|
Advances in understanding and management of myeloproliferative neoplasms, file e398c378-a34b-179a-e053-3705fe0a4cff
|
223
|
|
Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia, file e398c37b-a852-179a-e053-3705fe0a4cff
|
211
|
|
Effect of mutation order on myeloproliferative neoplasms, file e398c379-99da-179a-e053-3705fe0a4cff
|
208
|
|
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction., file e398c378-a7e5-179a-e053-3705fe0a4cff
|
204
|
|
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis, file e398c37c-930f-179a-e053-3705fe0a4cff
|
189
|
|
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis., file e398c37b-9db7-179a-e053-3705fe0a4cff
|
188
|
|
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance., file e398c37b-a16a-179a-e053-3705fe0a4cff
|
171
|
|
JAK2V617F-homozigosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant clone, file e398c378-d7a2-179a-e053-3705fe0a4cff
|
170
|
|
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms., file e398c378-b6c7-179a-e053-3705fe0a4cff
|
165
|
|
Targeted deep sequencing in polycythemia vera and essential thrombocythemia, file e398c37e-84a3-179a-e053-3705fe0a4cff
|
163
|
|
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients, file e398c37b-9839-179a-e053-3705fe0a4cff
|
151
|
|
EZH2 mutational status predicts poor survival in myelofibrosis., file e398c37a-bf37-179a-e053-3705fe0a4cff
|
150
|
|
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells, file e398c37b-98d8-179a-e053-3705fe0a4cff
|
147
|
|
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial, file e398c379-9e7b-179a-e053-3705fe0a4cff
|
143
|
|
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2., file e398c37a-43a4-179a-e053-3705fe0a4cff
|
142
|
|
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia., file e398c37b-a762-179a-e053-3705fe0a4cff
|
140
|
|
Role of miR-34a-5p in hematopoietic progenitor cells proliferation and fate decision: Novel insights into the pathogenesis of primary myelofibrosis, file e398c37b-98d7-179a-e053-3705fe0a4cff
|
139
|
|
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis., file e398c378-ced2-179a-e053-3705fe0a4cff
|
135
|
|
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium, file e398c37b-a0cb-179a-e053-3705fe0a4cff
|
135
|
|
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms, file e398c379-9abf-179a-e053-3705fe0a4cff
|
127
|
|
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis, file e398c379-9f82-179a-e053-3705fe0a4cff
|
125
|
|
Molecular mechanisms associated with leukaemic transformation of MPL-mutant myeloproliferative neoplasms., file e398c37b-a0cf-179a-e053-3705fe0a4cff
|
121
|
|
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition., file e398c378-b001-179a-e053-3705fe0a4cff
|
119
|
|
Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells, file e398c379-9c30-179a-e053-3705fe0a4cff
|
116
|
|
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants, file e398c37e-e4a3-179a-e053-3705fe0a4cff
|
115
|
|
Diagnostic and therapeutic challenges in mast cell sarcoma, file cbe32a33-74e8-4eb3-af28-c662b44ac259
|
112
|
|
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives, file e398c378-a5db-179a-e053-3705fe0a4cff
|
110
|
|
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms., file e398c37a-54a5-179a-e053-3705fe0a4cff
|
110
|
|
Circ RNAs are here to stay: A perspective on the MLL recombinome, file e398c37e-de1e-179a-e053-3705fe0a4cff
|
106
|
|
Cardiovascular events and intensity of treatment in polycythemia vera., file e398c379-e089-179a-e053-3705fe0a4cff
|
105
|
|
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis, file e398c37b-9269-179a-e053-3705fe0a4cff
|
105
|
|
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera., file e398c37b-a7dc-179a-e053-3705fe0a4cff
|
105
|
|
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, file e398c37b-a1ba-179a-e053-3705fe0a4cff
|
103
|
|
Chronic myeloproliferative neoplasms: a collaborative approach., file e398c37b-6122-179a-e053-3705fe0a4cff
|
100
|
|
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms, file e398c37b-9338-179a-e053-3705fe0a4cff
|
98
|
|
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis, file e398c37b-91f0-179a-e053-3705fe0a4cff
|
92
|
|
miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6, file e398c37b-cf2c-179a-e053-3705fe0a4cff
|
88
|
|
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients, file e398c37e-e6c1-179a-e053-3705fe0a4cff
|
80
|
|
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis, file e398c37c-e9e8-179a-e053-3705fe0a4cff
|
78
|
|
STAT1 activation in association with JAK2 exon 12 mutations, file e398c37b-a1b6-179a-e053-3705fe0a4cff
|
68
|
|
Results from HARMONY: an open-label, multicentre, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis, file e398c37e-e4a0-179a-e053-3705fe0a4cff
|
65
|
|
Characterisation and discovery of novel miRNAs andmoRNAs in JAK2V617F mutated SET2 cells, file e398c378-c3f0-179a-e053-3705fe0a4cff
|
59
|
|
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms, file e398c37b-98a2-179a-e053-3705fe0a4cff
|
58
|
|
FLT3-mediated p38-MAPK activation participates in the control ofmegakaryopoiesis in primary myelofibrosis., file e398c37b-9d50-179a-e053-3705fe0a4cff
|
54
|
|
Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis, file e398c37e-de16-179a-e053-3705fe0a4cff
|
53
|
|
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis., file e398c378-a7e7-179a-e053-3705fe0a4cff
|
43
|
|
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion, file e398c37c-b86a-179a-e053-3705fe0a4cff
|
24
|
|
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk ofsplanchnic vein thrombosis., file e398c37a-4dc4-179a-e053-3705fe0a4cff
|
23
|
|
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study, file e398c382-3e4c-179a-e053-3705fe0a4cff
|
21
|
|
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project, file 9ab2c970-d6dd-4f57-8c91-249fb92ba35a
|
20
|
|
Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia, file c30040df-9dcb-4220-b883-e7f7f04db448
|
13
|
|
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis, file e398c381-ec2a-179a-e053-3705fe0a4cff
|
6
|
|
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis, file 1bad6db2-b573-4f4e-bf9a-7baf80701d1c
|
5
|
|
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients, file e398c381-f0dc-179a-e053-3705fe0a4cff
|
4
|
|
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis, file 3bd5c24b-01ee-4d48-89e4-f7038f518897
|
3
|
|
Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data, file e398c37e-de20-179a-e053-3705fe0a4cff
|
3
|
|
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib, file 391ace5a-5bf4-41f1-bb6a-1f8444ad6c74
|
2
|
|
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis., file e398c37a-0a58-179a-e053-3705fe0a4cff
|
2
|
|
Rationale for combination therapies in myelofibrosis, file e398c37b-9ae6-179a-e053-3705fe0a4cff
|
2
|
|
MIPSS701 version 2.0: Mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis, file e398c37e-de0c-179a-e053-3705fe0a4cff
|
2
|
|
Incidence of blast phase in myelofibrosis according to anemia severity, file 0ac655b8-1d28-41ee-a8ea-893874f0e38f
|
1
|
|
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms, file 236d75b2-a7d6-4c79-86b8-4575a3e04127
|
1
|
|
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19, file 60b53a60-14be-400d-94a6-74d1a77e6439
|
1
|
|
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value., file e398c379-e459-179a-e053-3705fe0a4cff
|
1
|
|
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients, file e398c37b-98a3-179a-e053-3705fe0a4cff
|
1
|
|
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation, file e398c37b-98a4-179a-e053-3705fe0a4cff
|
1
|
|
Struggling with myelofibrosis-associated anemia., file e398c37b-9bed-179a-e053-3705fe0a4cff
|
1
|
|
What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?, file e398c37b-a0bf-179a-e053-3705fe0a4cff
|
1
|
|
Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations., file e398c37b-a5a3-179a-e053-3705fe0a4cff
|
1
|
|
Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation., file e398c37b-a6c9-179a-e053-3705fe0a4cff
|
1
|
|
Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease., file e398c37b-a887-179a-e053-3705fe0a4cff
|
1
|
|
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation, file e398c37c-85d9-179a-e053-3705fe0a4cff
|
1
|
|
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis, file e398c37c-9000-179a-e053-3705fe0a4cff
|
1
|
|
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients, file e398c37c-cb72-179a-e053-3705fe0a4cff
|
1
|
|
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms, file e398c37e-84a5-179a-e053-3705fe0a4cff
|
1
|
|
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project, file e398c37e-84a7-179a-e053-3705fe0a4cff
|
1
|
|
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea, file e398c37e-e6b8-179a-e053-3705fe0a4cff
|
1
|
|
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation, file e398c37e-e6bd-179a-e053-3705fe0a4cff
|
1
|
|
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease, file e398c381-9832-179a-e053-3705fe0a4cff
|
1
|
|
AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance – MYNERVA-GIMEMA AML1919 trial, file e398c381-b1ea-179a-e053-3705fe0a4cff
|
1
|
|
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs, file e398c381-d10b-179a-e053-3705fe0a4cff
|
1
|
|
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study, file e398c381-eb93-179a-e053-3705fe0a4cff
|
1
|
|
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study, file e398c381-ec2b-179a-e053-3705fe0a4cff
|
1
|
| Totale |
13.816 |